Qidni's CEO, Dr. Morteza Ahmadi, presented at 2024 Canadian Society of Nephrology - CSN/SCN conference in Montreal at the session "The Kidney Foundation of Canada- Let’s keep making history / Le Fondation du rein- Continuons d’écrire l’histoire". In this invited talk, he presented Qidni's story and the most recent progress of the company. He also shared his vision for the future of the dialysis industry and participated in a fireside chat after his talk.
Qidni Labs Inc.’s Post
More Relevant Posts
-
"🚨🌟 The Top 10 Nephrology Stories of the year! 🔥🔥 💥From groundbreaking research to clinical breakthroughs, these are the must-know updates in kidney care. 🧠💡 👏👏Great infographic by @brian_rifkin ✔️Join us at the next #NephJC to discuss how these discoveries are shaping the future! 📊 #KidneyHealth #Top10Stories"
-
-
Watson Clinic Nephrology specialist Dr. Steven Achinger, alongside researchers from the University of South Florida and the University of California, has authored an informative new study on the threat of low blood sodium levels in patients who take thiazide diuretics. Read more about this important research at https://shorturl.at/HuBYl.
-
-
How does your practice measure up? 📊 RPA’s benchmarking survey provides real-world data on nephrology practices nationwide—essential for evaluating the success of your business. Exclusive to nephrology, this data offers key insights without revealing individual practice details: https://lnkd.in/gvv4iZR6 #BenchmarkingSurvey #NephrologyInsights #PracticeManagement
-
-
Sacubitril/valsartan shows potential renal benefits over ACE inhibitor/ARB in patients with malignant hypertension-associated thrombotic microangiopathy (mHTN-associated TMA), this study’s findings suggest. https://ja.ma/3MJpQGe
-
In our latest GN in Ten episode, Koyal Jain and Kenar Jhaveri chat with Jula Inrig about endothelin antagonism, sparsentan, the art and science of clinical trial design, clinical research careers outside academia, and how we got to this "golden era" of nephrology trials. https://lnkd.in/es_sAPyu
Episode 5: Industry Perspective with Jula Inrig: Endothelin Antagonism, IgAN, FSGS, Clinical Trial Career Paths, and the New Era of Nephrology Trials | GN in Ten | Episode 5
https://transistor.fm
-
In a recent episode of Nephrology Today, Brian O'Dea, CEO of NANI, the largest nephrology practice in the United States, discusses the intricacies of nephrologist recruitment and what makes NANI an attractive choice for kidney care specialists. Listen here h ttps://https://lnkd.in/gY9T2xHb
Brian O'Dea, CEO of NANI on Nephrologist Recruitment by Nephrology Today
podcasters.spotify.com
-
🔬 Uncover the complexities of this unique case and its implications for treatment. Read the new published case report in our journal Medical Sciences MDPI titled "Double Hit of Hydroxichloroquine and Amiodarone Induced Renal Phospholipidosis in a Patient with Monoclonal Gammopathy and Sclerodermiform Syndrome: A Case Report and Review of the Literature". 👥 Authors: De la Flor, J. C. et al. 🔗 Read the article here: https://lnkd.in/dBG-XQJY #MedicalResearch #CaseReport #Hydroxychloroquine #Amiodarone
Double Hit of Hydroxichloroquine and Amiodarone Induced Renal Phospholipidosis in a Patient with Monoclonal Gammopathy and Sclerodermiform Syndrome: A Case Report and Review of the Literature
mdpi.com
-
The International Society of Nephrology collaborative quality framework to support safe and effective dialysis provision in resource-challenged settings. 2024 from Kidney International Reports https://lnkd.in/evdu-i5b
-
-
Drawing on his extensive knowledge in arterial hypertension, internal medicine, and nephrology, Prof. Dr. med. Markus van der Giet enriches our advisory board. Here is his perspective on TIMELY's potential impact. #EUTIMELY #meettheteam
-
-
Leerink Center for Pharmacoeconomics (CPE) released their next CPE Exclusive, focused on Attruby for Transthyretin Amyloid Cardiomyopathy. Read the full report at: https://lnkd.in/eWE98CnV The Leerink Center for Pharmacoeconomics is a division of MEDACorp which is an affiliate of Leerink Partners.
-
